Alzheimer’s & Parkinson’s Drug Development Summit

February 3-5, 2026 | Boston, MA

The approval of the first anti-amyloid drugs has resurrected the neurodegenerative disease space, opening the door for enhanced competition and innovation to develop novel disease-modifying therapies. However, as challenges remain in the clinical adoption of Lecanemab and Donanemab, the field needs to navigate the move towards disease-modifying therapeutics.

Capitalizing on the surge of innovation across new targets, lessons learned from clinical setbacks, groundbreaking progress in blood-based diagnostics, and more, the 14th Alzheimer’s & Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical and regulatory.Presentatio

Presentation

Tuesday 3rd February 2026 | 1:30 pm ET
SPEAR UltraDetect™ for Neurodegenerative Biomarker Detection & Monitoring

• A novel immunoassay platform enabling ultra-sensitive detection of neurological biomarker detection 
• Quantitative plasma pTau 217 measurement with enhanced discrimination of amyloid positivity in both memory clinic and community cohorts  
• Beyond pTau 217: advancing Alzheimer’s and Parkinson’s disease research with the SPEAR UltraDetect™ biomarker solution